PERSPECTIVE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $23.60 million as of 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2025-11-10
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $23.60M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $98.70M.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $77.50M.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $90.90M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2025-09-30 | $23.60M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $98.70M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $77.50M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $90.90M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |